Not finding it? Sign in to also search OpenAlex live.
-
Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma
Niels W.C.J. van de Donk, Sébastien Anguille, Jo Caers, Marte C. Liefaard, Christian J. Jacques, Anna D.D. van Muyden
1citations -
Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).2021 Journal of Clinical Oncology conference-abstract Medicine Prostate Cancer Treatment and Research
Rahul Raj Aggarwal, Ana Maria Aparicio, Axel Heidenreich, Shahneen Kaur Sandhu, Yiran Zhang, Mark Salvati, +1 more
14citations -
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.2023 Journal of Clinical Oncology conference-abstract Medicine Endometrial and Cervical Cancer Treatments Open access
Jessica Nell McAlpine, Kathy Chai-Zung Han, Mary A. Kinloch, Maroie Barkati, Sarah Elizabeth Ferguson, Anthony Fyles, +13 more
8citations -
A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.2025 Journal of Clinical Oncology conference-abstract Medicine Ocular Oncology and Treatments Open access
Matteo Salvatore Carlino, Reinhard Dummer, Tanja Gromke, Jessica Cecile Hassel, Ellen Kapiteijn, Damien Kee, +12 more
6citations -
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
Natalia Tovar, Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Sergi Betriu, Daniel Esteban, Ana Triguero, +5 more
5citations -
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Letícia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, +8 more
5citations -
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Marie José Kersten, Kirsten Saevels, Évelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, +9 more
3citations -
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Flore Sicre de Fontbrune, Anna Gayà, Ilene Ceil Weitz, David J. Kuter, David J. Araten, +15 more
0citations -
Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
Thaïs M. L. Tong, Mark Christiaan Burgmans, Monique K. van der Kooij, Frank M. Speetjens, Arian R. van Erkel, Rutger W. van der Meer, +11 more
0citations -
A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor.2023 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access
Hans A. J. Gelderblom, Vivek A. Bhadri, Robert Lor Randall, Thomas J. Scharschmidt, William D. Tap, Laman Alani, +5 more
9citations -
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Laurien Joanna Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran, Jade M. van Berge Henegouwen, John R. Simes, Louisa Rose Hoes, +14 more
4citations -
Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy—The TRADE-hypo trial.
Farastuk Bozorgmehr, Jessica Juergens, Michaela Hammer‐Hellmig, Christian Meyer zum Bueschenfelde, Johannes Claßen, Juergen Alt, +14 more
4citations -
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).2020 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Volker Jochen Moebus, Hans-Joachim Lueck, Ekkehart Ladda, Peter Klare, Marcus Schmidt, Andreas Schneeweiß, +14 more
3citations -
Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC2024 Cancer Research conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses
Willemijn S.M.E. Theelen, Maurice Pérol, Kristof Cuppens, Ingel Demedts, Frank Borm, Bonne Biesma, +17 more
3citations -
Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study
Selim Corbacioglu, Jarl Mooyaart, Emmanuelle Polge, William Boreland, Jessica Lemaitre, Christophe Peczynski, +20 more
2citations